Shashi Sharma | Molecular Virology | Women Researcher Award

Posted on by sciencefather

Dr. Shashi Sharma | Molecular Virology | Women Researcher Award

Scientist at DRDO, India

Dr. Shashi Sharma is an accomplished researcher in the field of molecular virology and diagnostics, with a strong focus on portable and field-deployable genomic technologies. His contributions span across advanced viral genome characterization, molecular assay development, and epidemiological surveillance of high-risk viral pathogens. With over 60 international publications, more than 1000 kb of nucleotide sequence submissions to GenBank, and extensive work on respiratory, arboviral, and hemorrhagic fever viruses, Dr. Sharma has significantly contributed to both scientific knowledge and public health preparedness.

Publication Profile 

Scopus

Educational Background 🎓

Dr. Sharma likely holds:

  • A Doctorate (Ph.D.) in Molecular Biology, Virology, Biotechnology, or a closely related biomedical field.

  • Likely earlier qualifications include a Master’s and Bachelor’s degree in Life Sciences, Microbiology, or Biochemistry.

Professional Experience 💼

Dr. Sharma’s professional career reflects multidisciplinary expertise and translational research with national and global impact:

  • Development of portable sample preparation systems suitable for on-site pathogen detection.

  • Pioneering work in magnetic bead-based viral RNA isolation, enhancing sensitivity and field usability.

  • Expertise in isothermal amplification methods (like RT-PSR), enabling low-cost, rapid diagnostics.

  • Application of qRT-PCR technologies (TaqMan and SYBR Green) for routine and outbreak surveillance.

  • Conducting complete genome sequencing of Indian viral strains for GenBank database.

  • Phylogenetic and phylogeographic analysis to understand viral evolution and transmission dynamics.

  • Involvement in Test and Evaluation (T&E) of WPE (Whole Pathogen Exposure) diagnostic equipment.

  • Leading product development initiatives for diagnostic platforms, bridging lab research and commercial solutions.

Research Interests 🔬

  • Molecular diagnostics for infectious diseases

  • Rapid and isothermal nucleic acid detection methods (e.g., RT-PSR)

  • High-priority and Category A pathogens (e.g., KFDV, CCHFV)

  • Viral genomics and whole genome sequencing

  • Bioinformatics and evolutionary analysis

  • Public health biosurveillance technologies

  • Diagnostic device development and validation

  • Arboviruses and respiratory virus detection platforms

Awards and Honors🏆✨

  • 10 recognized awards, likely for:

    • Innovations in molecular diagnostics

    • Contributions to outbreak response and surveillance

    • Scientific publications and data sharing

    • Development of impactful diagnostic products

Conclusion🌟

Dr. Shashi Sharma stands out as a visionary in the fields of molecular virology, field diagnostics, and viral genomics. His broad spectrum of work—from laboratory assay design to field deployment of detection tools—demonstrates his ability to translate complex research into accessible public health solutions. His contributions in characterizing Indian viral genomes and enhancing diagnostic readiness for both emerging and endemic pathogens are of great value to national and global health security. With a strong portfolio of publications, innovations, and recognized awards, Dr. Sharma is well-suited for leadership roles in virology research, epidemic preparedness programs, and diagnostic innovation platforms.

Publications 📚

  1. 🧬 Molecular epidemiology of Kyasanur forest disease employing ONT-NGS: A field forward sequencing approach
    📝 Journal of Clinical Virology – Official Publication of the Pan American Society for Clinical Virology
    🔢 Citations: 0
    📍 Focus: Field-forward nanopore sequencing of KFD virus genomes

  2. 🧬 Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India
    📝 Frontiers in Medicine
    🔢 Citations: 1
    📍 Focus: Omicron evolution and structure-based genomic analysis

  3. 🧪 Simplified visual detection of Kyasanur Forest Disease virus employing Reverse Transcriptase-Polymerase Spiral Reaction (RT-PSR)
    📝 Virus Research
    🔓 Open Access
    🔢 Citations: 2
    📍 Focus: Portable and visual RT-PSR assay for KFD detection

  4. 🧬 Isolation and characterization of emerging Mpox virus from India
    📝 Journal of Medical Virology
    🔢 Citations: 5
    📍 Focus: Viral isolation, characterization, and genetic insights on Mpox

 

 

 

 

Amr Radwan | Immunology | Best Researcher Award

Posted on by sciencefather

Dr. Amr Radwan | Immunology | Best Researcher Award

Executive Medical Director at Regeneron, United Kingdom

Dr. Amr AH Radwan is a distinguished medical affairs leader with over two decades of global experience spanning clinical medicine, pharmaceutical medicine, immunology, gastroenterology, and strategic leadership in drug development and market access. Currently serving as Executive Medical Director at Regeneron Pharmaceuticals Inc., he brings deep scientific expertise and cross-functional insight to global medical affairs, particularly in immunological disorders and biologics. His work bridges the interface of clinical innovation, medical strategy, regulatory frameworks, and international healthcare markets.

Publication Profile 

Orcid

Educational Background 🎓

  • University of Cambridge

    • MB BChir (Bachelor of Medicine and Surgery), 1998

    • BA in Pathology (Honours), 1996

    • MA (Cantab), 1999

  • Royal College of Surgeons (Edinburgh)

    • AFRCS Part 1 (MCQ I & II), 2001

  • The Berne Institute, Kegworth

    • Foundation Training in Transactional Analysis Counselling & Psychotherapy, 2003

  • University of Cardiff

    • Diploma in Pharmaceutical Medicine, 2010

  • Royal College of Physicians

    • Membership of Faculty of Pharmaceutical Medicine, 2011

    • Specialist Training in Pharmaceutical Medicine, 2011

    • Fellowship, 2016

Professional Experience 💼

🏢 Regeneron Pharmaceuticals Inc. (2018–Present)

  • Executive Medical Director, Global Medical Affairs (2022–Present)

  • Senior Director, Global Medical Affairs (2019–2021)

  • Senior Director, Medical Affairs EU (2018–2019)

    • Key leadership in global immunology franchise across dermatology, respiratory, and GI indications (e.g., Dupilumab, Itepekimab).

    • Led GI franchise (EoE, EoG, eUC) strategy and ex-US medical organization restructuring.

    • Partnered with commercial, legal, and R&D teams for European, Canadian, and Japanese market expansions.

🏢 Aimmune Therapeutics Ltd. (2016–2018)

  • Vice President, Medical Affairs & Market Access

    • EU and global leadership for peanut allergy therapy; directed Drug Safety & PV, Market Access, and clinical trial governance.

🏢 Norgine Pharmaceuticals UK Ltd. (2014–2016)

  • Medical Director – EU

    • Led EU medical affairs, market access, PV, and NICE submission strategies; managed 8 country-level medical teams; oversaw clinical trials and licensing responses.

Research Interests 🔬

  • Pharmaceutical Medicine & Clinical Drug Development

  • Immunology, Dermatology, and Gastroenterology (e.g., EoE, PN, CRSwNP)

  • Allergic Disorders and Biologics (e.g., anti-IL33, anti-Fel D1)

  • Regulatory Compliance, Pharmacovigilance & Risk Management

  • Clinical Strategy and Market Access Studies

Awards and Honors🏆✨

  • Queens’ College Exhibition Prize (1994–1996)
    Awarded for First Class academic performance in Preclinical Sciences.

  • Fawcett Memorial Prize (1998)
    Recognized for Outstanding Communication Skills.

  • Fellowship of the Faculty of Pharmaceutical Medicine (2016)
    Awarded by Royal College of Physicians for significant contributions to Pharmaceutical Medicine.

Additional Credentials & Interests

  • Languages & Communication: Fluent in Arabic, English, and French.

  • Advanced Certifications:

    • IAM-trained motorcyclist (Institute of Advanced Motorists)

    • PADI Advanced & BSAC Sports Scuba Diving certifications

  • Hobbies:

    • Partner dancing (Argentine Tango, Blues, Modern Jive)

    • Literature, philosophy, and motorcycling

Conclusion🌟

Dr. Amr AH Radwan is a highly accomplished physician-leader whose contributions have shaped global medical affairs practices, especially in immunology and allergy-based therapeutics. His unique blend of clinical training, regulatory expertise, and cross-continental leadership makes him a significant figure in modern pharmaceutical medicine and translational healthcare strategy. He is well-suited for high-level recognition, awards, and continued leadership in both academic and industry circles.

Publications 📚

  1. 📄 A Real-World Study of Cumulative Steroid Burden Among Patients with Eosinophilic Esophagitis in the United States
    📰 Clinical Gastroenterology and Hepatology (Mar 2025)
    🔗 DOI: 10.1016/j.cgh.2025.01.010

  1. 📄 Baseline Disease Characteristics by Surgery History Among Patients with CRSwNP: AROMA Registry
    📰 American Journal of Otolaryngology (Mar 2025)
    🔗 DOI: 10.1016/j.amjoto.2024.104596

  1. 📄 Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: VOYAGE (Post Hoc)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Mar 2025)
    🔗 DOI: 10.1016/j.jaip.2024.11.014

  1. 📄 Burden of Eosinophilic Esophagitis in Adults and Adolescents: Real-World Analysis
    📰 Diseases of the Esophagus (Mar 3, 2025)
    🔗 DOI: 10.1093/dote/doaf024

  1. 📄 Dupilumab Efficacy in EoE Irrespective of Prior Swallowed Corticosteroids: LIBERTY EoE TREET Trial
    📰 Expert Review of Gastroenterology & Hepatology (Feb 2025)
    🔗 DOI: 10.1080/17474124.2025.2461516

  1. 📄 Current Smoker: A Clinical COPD Phenotype Affecting Disease Progression and Therapy Response
    📰 American Journal of Respiratory and Critical Care Medicine (Feb 12, 2025)
    🔗 DOI: 10.1164/rccm.202407-1379ci

  1. 📄 Dupilumab Induces Long-Term On-Treatment Clinical Remission in Type 2 Asthma
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Jan 2025)
    🔗 DOI: 10.1016/j.jaip.2024.10.009

  1. 📄 Disease Burden and Symptoms Impacting Quality of Life in Pediatric EoE Patients
    📰 Gastro Hep Advances (2024)
    🔗 DOI: 10.1016/j.gastha.2024.08.009

  1. 📄 Real-World Characteristics of Severe Asthma Patients Before Dupilumab: ProVENT Study
    📰 Respiration (2024)
    🔗 DOI: 10.1159/000535390

  1. 📄 Dupilumab Efficacy in Children With Type 2 Asthma on High-/Medium-Dose ICS (VOYAGE)
    📰 The Journal of Allergy and Clinical Immunology: In Practice (Dec 2024)
    🔗 DOI: 10.1016/j.jaip.2024.08.038